{Reference Type}: Journal Article
{Title}: Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.
{Author}: Clarfield L;Diamond L;Jacobson M;Clarfield L;Diamond L;Jacobson M;
{Journal}: Curr Oncol
{Volume}: 29
{Issue}: 3
{Year}: 03 2022 21
{Factor}: 3.109
{DOI}: 10.3390/curroncol29030172
{Abstract}: Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population. The majority of BRCA-associated OC is identified in the late stage, and no effective screening method has been proven to reduce mortality. Several pharmacologic and surgical options exist for risk-reduction of gynecologic malignancy in BRCA 1/2 mutation carriers. This review summarizes up-to-date research on pharmacologic risk-reducing interventions, including the oral contraceptive pill, acetylsalicylic acid/nonsteroidal anti inflammatory drugs (ASA/NSAID) therapy, and denosumab, and surgical risk-reducing interventions, including risk-reducing bilateral salpingo-oophorectomy, salpingectomy with delayed oophorectomy, and hysterectomy at the time of risk-reducing bilateral salpingo-oophorectomy.